Oregon Health & Science University
Portland, Oregon, 97239, United States
NCT Number: NCT05411835
The purpose of the study is to determine if an oral ketone beverage is safe and well-tolerated during moderate intensity exercise in participants with long-chain fatty acid oxidation disorders and if it will raise blood ketones to levels similar to that reported among normal healthy subjects.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Early Phase 1
Portland, Oregon, 97239, United States
Purpose: Subjects with long-chain fatty acid oxidation disorders (LC-FAOD) do not make ketones during fasting or with exercise. Ketones are an important alternative energy substrate during moderate exercise, sparing the oxidation of glucose and providing a source of ATP to the central nervous system and exercising muscle. Fatty acid oxidation in the liver is required to make ketones. Subjects with a LC-FAOD cannot generate ketones because of their block in fatty acid oxidation during exercise. Providing ketones in an oral ketone beverage may increase blood ketones with exercise to levels normally observed in humans.
Aim: To determine the safety and tolerability of an oral ketone beverage during moderate intensity exercise among subjects with a LC-FAOD compared to an isocaloric maltodextrin beverage, and to determine blood ketone concentrations.
Hypothesis: Oral consumption of a ketone beverage before moderate intensity exercise will be safe and well-tolerated, and will raise blood ketones among subjects with a LC-FAOD to concentrations similar to that reported in the literature among normal healthy subjects.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Mix of sodium, calcium, and magnesium salts of D-beta-hydroxybutyrate with nicotinamide riboside chloride, flavors and stevia sweetener
Other names: NKS
Maltodextrin with flavors and stevia sweetener
Time frame: 2 hours after product intake
Number of Adverse events
Time frame: 2 hours after product intake
Description of Adverse events: categorical
Time frame: 2 hours after product intake
Severity of adverse event: grade 1-5
Time frame: 2 hours after product intake
Yes/No related to product intake
Time frame: 2 hours after product intake
visual analogue scale (VAS) 0-10
Time frame: 2 hours after product intake
visual analogue scale (VAS) 0-10
Time frame: 2 hours after product intake
visual analogue scale (VAS) 0-10
Time frame: 2 hours after product intake
visual analogue scale (VAS) 0-10
Time frame: 2 hours after product intake
visual analogue scale (VAS) 0-10
Time frame: 2 hours after product intake
visual analogue scale (VAS) 0-10
Time frame: 20 minutes after moderate intensity exercise
plasma beta-hydroxybutyrate concentration
Time frame: 20 minutes after moderate intensity exercise
plasma CK concentration
Time frame: 20 minutes after moderate intensity exercise
serum glucose
Time frame: 20 minutes after moderate intensity exercise
serum lactate concentration
Time frame: peak 40 minute exercise
diastolic BP
Time frame: peak 40 minute exercise
systolic BP
Time frame: peak 40 minute exercise
Borg scale 1-20
Time frame: peak 40 minute exercise
VCO2/VO2 0.7 - 1.0
Time frame: peak 40 minute exercise
beats per minute
Oregon Health and Science University
Other
Safety and Tolerability of Oral Ketones and Exercise Among Patients With Long-chain Fatty Acid Oxidation Disorders
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01494051
Carnitine Palmitoyltransferase 2 Deficiency, Carnitine palmitoyl transferase 2 deficiency
View Trial DetailsNCT03655223
17 Alpha-Hydroxylase Deficiency, 3-Hydroxy-3-Methylglutaric Aciduria
Research Triangle Park, North Carolina, United States
View Trial DetailsNCT05687474
3-Hydroxy 3-Methyl Glutaric Aciduria, 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency
Liège, Wallonia, Belgium
View Trial DetailsNCT02517307
Carnitine Palmitoyltransferase II Deficiency, Late-Onset, Carnitine Palmitoyltransferase II Deficiency, Myopathic
Portland, Oregon, United States
View Trial Details